ClinicalTrials.gg
RecruitingNCT07114770Updated Aug 11, 2025

Explore the Impacts of One Session and Multiple Session Theta Burst Stimulation Over Cerebellum in Adults With Autism Spectrum Disorder

An interventional study of Theta Burst Stimulation (TBS, an advanced variant of repetitive transcranial magnetic stimulation) in Autism Spectrum Disorder and Theta Burst Stimulation, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Autism Spectrum Disorder by Chang Gung Memorial Hospital — 5 open to participants now, 7 under way, none of them phase 3. Autism Spectrum Disorder · Chang Gung Memorial Hospital.

Planned enrollment
3rd of 12
60 · median 60
Started
2025
with 1 other
No phase
11 of 15
4 open now
Registered
14th of 15
by date

Among the 15 studies in Autism Spectrum Disorder by Chang Gung Memorial Hospital, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 with no phase, and was the 14th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

5 of the 15 studies in Autism Spectrum Disorder by Chang Gung Memorial Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Autism Spectrum Disorder by Chang Gung Memorial Hospital, or all of them as a file.
02

Study summary

This study aims to establish a personalized theta burst stimulation (TBS, an advanced variant of repetitive transcranial magnetic stimulation, rTMS) protocol considering autistic idiosyncrasy (interindividual variability).

03

Conditions studied

  • Autism Spectrum Disorder
  • Theta Burst Stimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Autistic adults (≥18 years old), confirmed by Autism Diagnostic Observation Schedule.
  • severity level of ASD: level 1 or level 2

Inclusion criteria for typically developing control:

  • ≥18 years old without autism spectrum disorder

Exclusion criteria

Exclusion criteria for all participants:

  • Previous or current severe neurological disorders, especially epilepsy
  • Previous or current severe systemic diseases such as cardiovascular disease, diabetes or hypertension
  • Previous or current severe brain injury
  • Implementation of metal materials such as a pacemaker or medication pump
  • Previous or current severe psychiatric disorders such as schizophrenia, bipolar disorder, severe major depressive disorder or substance abuse
  • Pregnancy
  • Intracranial space occupied lesions
  • Previous brain surgery or central nerve system infection
  • Concurrent use of medications which increased the risk of seizure attack
  • Participate in another clinical trial within one month
  • With damaged skin at the stimulated region
  • With multiple sclerosis
  • With large ischemic scars
  • Have experienced sleep disorders during brain stimulation
  • Severe alcoholism
  • Concurrent use of antiepileptic drugs
  • Uncontrollable migraines due to increased intracranial pressure
  • Unsuitable for MRI (e.g. those with claustrophobia)
  • Unsuitable for EEG
  • severity level of ASD: level 3
  • Suicidal ideation within one year

Withdrawal criteria:

  • Seizure attack during the study period
  • Autistic symptoms worsened obviously during the study period (change of DSM-5 severity level)
  • Extreme agitation or irritability during the study period
  • Participants request
  • Clinical symptoms worsened obviously during study period
  • Start to use antiepileptic drugs during study period
  • Suicidal ideation or self-harm behaviors during study period
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Autistic adults

    Eligible participants are adults diagnosed with autism who meet the inclusion criteria of the study.

    Device: Theta Burst Stimulation (TBS, an advanced variant of repetitive transcranial magnetic stimulation)

  • Active comparator
    Typically developing adults

    Eligible participants are typically developing adults who meet the study's inclusion criteria.

    Device: Theta Burst Stimulation (TBS, an advanced variant of repetitive transcranial magnetic stimulation)

Interventions

  • DeviceTheta Burst Stimulation (TBS, an advanced variant of repetitive transcranial magnetic stimulation)

    Participants will receive a single session of either iTBS or cTBS (600 pulses) targeting the right cerebellar Crus I/II. One week after the initial TBS, they will receive another single session of iTBS or cTBS (600 pulses) at the same site.

06

What researchers measure

Primary outcomes

  1. Functional MRI (default mode network) - BOLD Signal

    Blood-oxygen-level-dependent (BOLD) signal is a measurement used in fMRI, which reflects the neural activity.

    Time frame: Baseline, Week 1, Week 2

  2. MEP amplitude

    MEP (motor evoked potential) amplitude is a measure of corticospinal excitability.

    Time frame: Baseline

  3. MEP amplitude

    MEP (motor evoked potential) amplitude is a measure of corticospinal excitability.

    Time frame: Week 1 (5 minutes post-TBS)

  4. MEP amplitude

    MEP (motor evoked potential) amplitude is a measure of corticospinal excitability.

    Time frame: Week 2 (5 minutes post-TBS)

  5. MEP amplitude

    MEP (motor evoked potential) amplitude is a measure of corticospinal excitability.

    Time frame: Week 1 (10 minutes post-TBS)

  6. MEP amplitude

    MEP (motor evoked potential) amplitude is a measure of corticospinal excitability.

    Time frame: Week 2 (10 minutes post-TBS)

  7. MEP amplitude

    MEP (motor evoked potential) amplitude is a measure of corticospinal excitability.

    Time frame: Week 1 (15 minutes post-TBS)

  8. MEP amplitude

    MEP (motor evoked potential) amplitude is a measure of corticospinal excitability.

    Time frame: Week 2 (15 minutes post-TBS)

  9. MEP amplitude

    MEP (motor evoked potential) amplitude is a measure of corticospinal excitability.

    Time frame: Week 1 (20 minutes post-TBS)

  10. MEP amplitude

    MEP (motor evoked potential) amplitude is a measure of corticospinal excitability.

    Time frame: Week 2 (20 minutes post-TBS)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2028, 35 months after the start.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 35 months is above that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 11, 2025
StartActual
Jul 29, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07114770
Responsible party
Sponsor
First posted
Aug 11, 2025
Start date
Jul 29, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 11, 2025

Study contacts

Hsing-Chang Ni, Ph.D
Contact
alanni0918@yahoo.com.tw
88633281200 ext. 2479

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion